 |
|
Mayo Clinic tests novel vaccine to treat aggressive brain tumors
October 23, 2007JACKSONVILLE, Fla. − A vaccine that has significantly increased life expectancy in early tests of patients with glioblastoma multiforme (GBM) − the most common, most aggressive form of brain cancer in adults − is now being offered through a clinical trial at Mayo Clinic in Jacksonville.
The vaccine represents a fresh and fairly simple approach to treating this cancer, says neurosurgeon Kent New, M.D., Ph.D., who will be leading the study at Mayo. About 40% of these tumors display a particular protein on their surface and the vaccine is designed to trick the patient's immune system into thinking the protein is "foreign" in order to mount a killing response.
"We are pleased to have a new and promising therapy to offer patients who want to participate in this clinical trial," says Dr. New. "The results, so far, have exceeded expectations."
Earlier studies of the vaccine at the University of Texas M. D. Anderson Cancer Center and Duke University Medical Center showed that median survival for the 39 GBM patients tested increased by more than 50 percent compared to the typical outcome. Additionally, the time it took tumors to begin growing again was doubled.
Dr. New cautioned, however, that it is unknown whether the vaccine added to standard treatment (surgery followed by radiation and chemotherapy) will ultimately produce any better outcome than the standard treatment alone. "By comparing standard therapy plus the vaccine to standard therapy alone, we hope to determine the true benefit of the vaccine" he says.
According to the National Cancer Institute, more than 20,000 people in the U.S. will be diagnosed with a brain tumor in 2007 and almost 13,000 will die from the cancer. GBM, the most common primary brain tumor, is considered incurable; most patients die within a year of diagnosis.
Twenty or more centers nationwide will participate in the clinical trial initially, which is being sponsored by Celldex Therapeutics, the manufacturer of the vaccine, known as CDX-110. The study will be conducted in two stages. Approximately 90 patients will participate in the first portion, and if results show an improvement in disease-free survival for the CDX-110 treated patients, an additional 285 participants will be enrolled in the expanded study, which will include more sites.
Patients newly diagnosed with GBM who enroll in the study will have surgery at the participating center, and tumors will be examined to see if they express the mutated epidermal growth factor receptor variant III (EGFRvIII) protein. Researchers believe that this protein, which is not expressed on normal brain cells, pushes cancer development, which is one reason why glioblastomas are so aggressive. The vaccine uses synthetic versions of EGFRvIII to stimulate both cell-mediated immunity (T cells that attack invaders) and humoral immune responses (B cells that provide ongoing immune surveillance).
Participating patients whose tumors exhibit EGFRvIII will be randomized (selected by chance) either to standard treatment alone or standard treatment plus CDX-110, and the agents will be used until the tumor progresses or patients develop side effects from the treatment.
Mayo Clinic
Earlier studies of the vaccine at the University of Texas M. D. Anderson Cancer Center and Duke University Medical Center showed that median survival for the 39 GBM patients tested increased by more than 50 percent compared to the typical outcome. Additionally, the time it took tumors to begin growing again was doubled.
Dr. New cautioned, however, that it is unknown whether the vaccine added to standard treatment (surgery followed by radiation and chemotherapy) will ultimately produce any better outcome than the standard treatment alone. "By comparing standard therapy plus the vaccine to standard therapy alone, we hope to determine the true benefit of the vaccine" he says.
According to the National Cancer Institute, more than 20,000 people in the U.S. will be diagnosed with a brain tumor in 2007 and almost 13,000 will die from the cancer. GBM, the most common primary brain tumor, is considered incurable; most patients die within a year of diagnosis.
Twenty or more centers nationwide will participate in the clinical trial initially, which is being sponsored by Celldex Therapeutics, the manufacturer of the vaccine, known as CDX-110. The study will be conducted in two stages. Approximately 90 patients will participate in the first portion, and if results show an improvement in disease-free survival for the CDX-110 treated patients, an additional 285 participants will be enrolled in the expanded study, which will include more sites.
Patients newly diagnosed with GBM who enroll in the study will have surgery at the participating center, and tumors will be examined to see if they express the mutated epidermal growth factor receptor variant III (EGFRvIII) protein. Researchers believe that this protein, which is not expressed on normal brain cells, pushes cancer development, which is one reason why glioblastomas are so aggressive. The vaccine uses synthetic versions of EGFRvIII to stimulate both cell-mediated immunity (T cells that attack invaders) and humoral immune responses (B cells that provide ongoing immune surveillance).
Participating patients whose tumors exhibit EGFRvIII will be randomized (selected by chance) either to standard treatment alone or standard treatment plus CDX-110, and the agents will be used until the tumor progresses or patients develop side effects from the treatment.
Mayo Clinic
Brain Tumor News and Current Brain Tumor Events RSSBarrow researchers identify a new approach to detect the early progression of brain tumors
Researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center recently participated in a pilot study with the Montreal Neurological Institute that suggests a certain type of MRI scanning can detect when a patient is failing brain tumor treatment before symptoms appear.
Childhood brain tumor traced to normal stem cells gone bad
An aggressive childhood brain tumor known as medulloblastoma originates in normal brain "stem" cells that turn malignant when acted on by a known mutant, cancer-causing oncogene, say researchers from Dana-Farber Cancer Institute and the University of California, San Francisco (UCSF).
Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
In a study using laboratory animals, researchers found that medications commonly prescribed for erectile dysfunction opened a mechanism called the blood-brain tumor barrier and increased delivery of cancer-fighting drugs to malignant brain tumors.
Certain anticancer agents could be harmful to patients with heart disease
A set of promising new anticancer agents could have unforeseen risks in individuals with heart disease, suggests research at Washington University School of Medicine in St. Louis.
St. Jude finds young age may give survival advantage to children with certain brain tumors
St. Jude Children's Research Hospital investigators have shown that children under 3 years old who have a brain tumor called diffuse pontine glioma (DPG) appear to have a better outcome than older children with the same cancer.
Brown Chemists Create Cancer-Detecting Nanoparticles
A team led by a Brown University chemist has created the smallest iron oxide nanoparticles to date for cancer detection by magnetic resonance imaging (MRI). The magnetic nanoparticles operate like tiny guided missiles, seeking and attaching themselves to malignant tumor cells. Once they bind, the particles emit stronger signals that MRI scans can detect.
MRI: A window to genetic properties of brain tumors
Doctors diagnose and prescribe treatment for brain tumors by studying, under a microscope, tumor tissue and cell samples obtained through invasive biopsy or surgery.
Protein protects embryonic stem cells' versatility and self-renewal
A protein known as REST blocks the expression of a microRNA that prevents embryonic stem cells from reproducing themselves and causes them to differentiate into specific cell types, scientists at The University of Texas M. D. Anderson Cancer Center report in the journal Nature.
St. Jude finds signaling system that halts the growth of a childhood brain cancer
A discovery by St. Jude Children's Research Hospital scientists suggests a safer way to treat medulloblastoma, a rare but often fatal childhood brain tumor. The group found that one of the brain's signaling pathways inhibits the growth of the highly aggressive cancer cells.
Paradigm shift: Switch for programmed cell death promotes spread of glioblastoma
Malignant tumors have usually lost their ability to destroy themselves by programmed cell death, or apoptosis. Therefore, tumors are often resistant to chemotherapy or radiation therapy, whose effect is based on forcing tumor cells to commit suicide.
More Brain Tumor News Articles
 | Death Be Not Proud (P.S.) by John J. Gunther Johnny Gunther was only seventeen years old when he died of a brain tumor. During the months of his illness, everyone near him was unforgettably impressed by his level-headed courage, his wit and quiet friendliness, and, above all, his unfaltering patience through times of despair. This deeply moving book is a father's memoir of a brave, intelligent, and spirited boy.... |
 | EEG on DVD - Adult: An Interactive Reading Session by Richard P., M.D. Brenner Here is the first fully interactive tool that simulates an actual EEG lab reading session. EEG on DVD: Adult - An Interactive Reading Session teaches EEG interpretation to neurology residents, clinical neurophysiology fellows, and neurologists, using 200 EEG cases, over 400 EEGs, and a self-testing section.A wide variety of adult EEGs are presented, covering diseases such as epilepsy, brain... |
 | Damn The Statistics, I Have a Life to Live!: Coping with a Brain Tumor My Personal Story by H. Charles Wolf |
 | A Journey Round My Skull (New York Review Books Classics) by Frigyes Karinthy The distinguished Hungarian author Frigyes Karinthy was sitting in a Budapest café, wondering whether to write a long-planned monograph on modern man or a new play, when he was disturbed by the roaring—so loud as to drown out all other noises—of a passing train. Soon it was gone, only to be succeeded by another. And another. Strange, Karinthy thought, it had been years since Budapest... |
 | Curveball: When Life Throws You a Brain Tumor by Liz Holzemer Life seemed idyllic for thirty-two-year-old Liz Holzemer. Wife of Major League Baseball pitcher Mark Holzemer, Liz was enjoying a successful career as a journalist when an MRI revealed a baseball-size brain tumor she soon found out was called meningioma. Told with clarity and unwavering humor, this book is an inspirational and informative account of one woman's battle for her life. It shows... |
 | I Had Brain Surgery, What's Your Excuse? by Suzy Becker For years Suzy Becker, author of The New York Times bestseller All I Need to Know I Learned from My Cat, literally lived by her wits--her imagination, intelligence, ideas, passion. During much of that time she was also suffering seizures. But they came secretly in the middle of the night, and were probably stress-related, or so one doctor said. Then a seizure (and a second opinion) led to a round... |
 | Living with a Brain Tumor: Dr. Peter Black's Guide to Taking Control of Your Treatment by Peter Black Each year, 100,000 people in the United States are diagnosed with a brain tumor. With his new book, Dr. Peter Black fills a gap in the lay readership, providing an accessible medical resource for adult patients and their families. Dr. Black, who has operated on more than 3,000 patients with brain tumors, is uniquely qualified to discuss both clinical treatment of and research into brain tumors.... |
 | Brain Tumors: Leaving the Garden of Eden--A Survival Guide to Diagnosis, Learning the Basics, Getting Organized, and Finding Your Medical Team by Paul M. Zeltzer A guidebook for the 150,000+ people/ year and families affected by brain tumors. This book will help you learn the basics about diagnosis, getting organized and finding your medical team. Included are chapters on all major types of brain tumors & metastases, glossary, medications, using the Internet to search for information, and getting a second opinion. "Brain Tumors:Leaving the Garden of... |
 | We Bought a Zoo: The Amazing True Story of a Young Family, a Broken Down Zoo, and the 200 Wild Animals That Changed Their Lives Forever by Benjamin Mee Benjamin Mee decided to uproot his family and move them to an unlikely new home: a dilapidated zoo on the English countryside, complete with over 200 exotic animals. It was his dream to refurbish the zoo and run it as a family business. There was much work to be done, and none of it easy. Tigers broke loose, money ran low, the staff grew skeptical, and family tensions ran high. Then tragedy... |
 | Never Change by Elizabeth Berg Elizabeth Berg has a single great gift as a novelist. She creates heroines who are stuck and unhappy, yet deeply sympathetic. This may seem like an easy trick to pull off, but it's not. Think about it: usually when a character is mired in a problem--especially a problem stemming from her own reluctance to change, or fear of commitment, or lack of identity--the reader is ready within a few dozen... |
| © 2008 BrightSurf.com |